Adaptimmune Therapeutics PLC – (NASDAQ:ADAP)’s share price passed below its 50-day moving average during trading on Tuesday . The stock has a 50-day moving average of $3.49 and traded as low as $2.84. Adaptimmune Therapeutics shares last traded at $3.08, with a volume of 449,130 shares changing hands.
A number of equities analysts recently commented on ADAP shares. Zacks Investment Research cut shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a research report on Tuesday, March 3rd. ValuEngine raised shares of Adaptimmune Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday, December 3rd. Finally, BidaskClub lowered shares of Adaptimmune Therapeutics from a “buy” rating to a “hold” rating in a report on Wednesday, March 11th. Four analysts have rated the stock with a hold rating and five have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus target price of $6.03.
The firm has a market cap of $370.70 million, a P/E ratio of -2.19 and a beta of 1.42. The company has a current ratio of 3.51, a quick ratio of 3.51 and a debt-to-equity ratio of 0.19. The business’s fifty day simple moving average is $3.46 and its 200-day simple moving average is $2.10.
In other news, Director James Noble sold 300,000 shares of Adaptimmune Therapeutics stock in a transaction dated Monday, January 13th. The shares were sold at an average price of $4.67, for a total transaction of $1,401,000.00. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, major shareholder Peter W. Sonsini bought 7,500,000 shares of the business’s stock in a transaction dated Friday, January 24th. The shares were bought at an average cost of $0.67 per share, for a total transaction of $5,025,000.00. The disclosure for this purchase can be found here. Insiders have sold a total of 317,323 shares of company stock worth $1,447,506 in the last ninety days. Insiders own 22.36% of the company’s stock.
Several institutional investors and hedge funds have recently made changes to their positions in the company. Tower Research Capital LLC TRC raised its holdings in shares of Adaptimmune Therapeutics by 21,372.0% during the third quarter. Tower Research Capital LLC TRC now owns 21,472 shares of the biotechnology company’s stock valued at $32,000 after purchasing an additional 21,372 shares during the last quarter. Raymond James & Associates raised its holdings in shares of Adaptimmune Therapeutics by 13.7% during the fourth quarter. Raymond James & Associates now owns 29,411 shares of the biotechnology company’s stock valued at $35,000 after purchasing an additional 3,546 shares during the last quarter. Partnervest Advisory Services LLC purchased a new position in shares of Adaptimmune Therapeutics during the fourth quarter valued at approximately $42,000. Geode Capital Management LLC raised its holdings in shares of Adaptimmune Therapeutics by 53.1% during the fourth quarter. Geode Capital Management LLC now owns 98,007 shares of the biotechnology company’s stock valued at $117,000 after purchasing an additional 34,007 shares during the last quarter. Finally, Polygon Management Ltd. raised its holdings in shares of Adaptimmune Therapeutics by 71.5% during the fourth quarter. Polygon Management Ltd. now owns 857,311 shares of the biotechnology company’s stock valued at $1,029,000 after purchasing an additional 357,311 shares during the last quarter. 49.88% of the stock is currently owned by hedge funds and other institutional investors.
About Adaptimmune Therapeutics (NASDAQ:ADAP)
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on providing novel cell therapies primarily to patients with solid tumors in the United States. The company's specific peptide enhanced affinity receptor T-cell platform enables it to identify cancer targets. It is involved in developing ADP-A2M10 that is in the phase I clinical trials for the treatment of non-small cell lung cancer (NSCLC), as well as urothelial, melanoma, and head and neck cancers; ADP-A2M4 that is in phase I clinical trial for solid tumor indication that include urothelial, melanoma, head and neck, ovarian, NSCLC, esophageal, gastric, synovial sarcoma, and myxoid round cell liposarcoma cancers; and ADP-A2AFP that is in phase I clinical trial for hepatocellular carcinoma.
Featured Story: How to calculate compound interest
Receive News & Ratings for Adaptimmune Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Adaptimmune Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.